Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Large Growth in Short Interest

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 10,189 shares, an increase of 67.9% from the May 14th total of 6,068 shares. Based on an average trading volume of 7,808 shares, the short-interest ratio is presently 1.3 days. Currently, 0.0% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Molecular Partners Stock Down 6.7%

NASDAQ MOLN traded down $0.28 during trading hours on Monday, reaching $3.84. The company’s stock had a trading volume of 5,738 shares, compared to its average volume of 4,548. Molecular Partners has a 1 year low of $3.41 and a 1 year high of $5.36. The company has a market capitalization of $154.84 million, a price-to-earnings ratio of -1.98 and a beta of 1.07. The firm’s 50-day moving average price is $4.11 and its 200-day moving average price is $4.31.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). Equities research analysts anticipate that Molecular Partners will post -1.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MOLN has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Molecular Partners in a report on Wednesday, April 22nd. TD Cowen restated a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Molecular Partners has a consensus rating of “Hold” and an average target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.